<DOC>
	<DOC>NCT00780416</DOC>
	<brief_summary>This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b (PEG-IFN) and Ribavirin (RBV) in treatment-naïve patients with (Genotype 1) hepatitis C.</brief_summary>
	<brief_title>Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Genotype 1, chronic hepatitis C Treatmentnaïve (patient who has received no previous interferon based treatment for hepatitis C) Able and willing to follow contraception requirements Cirrhosis of the liver or hepatic failure Hepatitis B surface antigenpositive or HIV antibodiespositive History of, or concurrent hepatocellular carcinoma History of, or concurrent depression, schizophrenia; or suicide attempt in the past Pregnant, lactating, or suspected pregnant patients, or male patients whose female partner is pregnant</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Protease Inhibitor</keyword>
	<keyword>Telaprevir</keyword>
	<keyword>Peginterferon Alfa-2b</keyword>
	<keyword>Ribavirin</keyword>
</DOC>